Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 4Pancreatic Neoplasms 3Hypertension, Portal 3Colorectal Neoplasms 2Stomach Neoplasms 1Melanoma 1Liver Neoplasms 1Liver Cirrhosis 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Irinotecan 10Fluorouracil 10Leucovorin 9Bevacizumab 9Gemcitabine 8Paclitaxel 7Cisplatin 7Capecitabine 7Oxaliplatin 6130-nm albumin-bound paclitaxel 6Albumin-Bound Paclitaxel 5napabucasin 4Sorafenib 4Drug Therapy 4Cetuximab 4pembrolizumab 3apatinib 3Radiotherapy 3Ocoxin 3Imatinib Mesylate 3Folfox protocol 3Everolimus 3tislelizumab 2spartalizumab 2palbociclib 2entinostat 2encorafenib 2camrelizumab 2anlotinib 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Digestive System Neoplasms × Propranolol × Gastrointestinal × Clear all
NCT06775080 2025-01-14

The Use of Propranolol in the Perioperative Period of Resectable Gastrointestinal Tumors

Huashan Hospital

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡